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Abstract
Background: Estrogens regulate diverse physiological processes in various tissues through genomic and non-
genomic mechanisms that result in activation or repression of gene expression. Transcription regulation upon
estrogen stimulation is a critical biological process underlying the onset and progress of the majority of breast
cancer. Dynamic gene expression changes have been shown to characterize the breast cancer cell response to
estrogens, the every molecular mechanism of which is still not well understood.
Results: We developed a modulated empirical Bayes model, and constructed a novel topological and temporal
transcription factor (TF) regulatory network in MCF7 breast cancer cell line upon stimulation by 17b-estradiol
stimulation. In the network, significant TF genomic hubs were identified including ER-alpha and AP-1; significant
non-genomic hubs include ZFP161, TFDP1, NRF1, TFAP2A, EGR1, E2F1, and PITX2. Although the early and late
networks were distinct (<5% overlap of ERa target genes between the 4 and 24 h time points), all nine hubs were
significantly represented in both networks. In MCF7 cells with acquired resistance to tamoxifen, the ERa regulatory
network was unresponsive to 17b-estradiol stimulation. The significant loss of hormone responsiveness was
associated with marked epigenomic changes, including hyper- or hypo-methylation of promoter CpG islands and
repressive histone methylations.
Conclusions: We identified a number of estrogen regulated target genes and established estrogen-regulated
network that distinguishes the genomic and non-genomic actions of estrogen receptor. Many gene targets of this
network were not active anymore in anti-estrogen resistant cell lines, possibly because their DNA methylation and
histone acetylation patterns have changed.
Background
Estrogens regulate diverse physiological processes in
reproductive tissues and in mammary, cardiovascular,
bone, liver, and brain tissues [1]. The most potent and
dominant estrogen in human is 17b-estradiol (E2). The
biological effects of estrogens are mediated primarily
through estrogen receptors a and b (ER-a and -b),
ligand-inducible transcription factors of the nuclear
receptor superfamily. Estrogens control multiple
functions in hormone-responsive breast cancer cells [2],
and ERa, in particular, plays a major role in the etiology
of the disease, serving as a major prognostic marker and
therapeutic target in breast cancer management [2].
Binding of hormone to receptor facilitates both geno-
mic and non-genomic ERa activities to either activate
or repress gene expression. Target gene regulation by
ERa is accomplished primarily by four distinct mechan-
isms (additional file 1) [3-5]: (i) ligand-dependent geno-
mic action (i.e., direct binding genomic action or
“DBGA”), in which ERa binds directly to estrogen
response elements (ERE) in DNA. Candidate DBGA
gene targets include PR and Bcl-2; (ii) ligand-dependent,
ERE-independent genomic action (i.e., indirect binding
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lates genes via protein-protein interactions with other
transcription factors (such as c-Fos/c-Jun (AP-1), Sp1,
and nuclear factor-B( N F B)) [4]. Target I-DBGA
genes include MMP-1 and IGFNP4; (iii) Ligand-inde-
pendent ERa signaling, in which gene activation occurs
through second messengers downstream of peptide
growth factor signaling (e.g., EGFR, IGFR, GPCR path-
ways). Ligand-independent mechanism can be either
DBGA or I-DBGA. These pathways alter intracellular
kinase and phosphatase activity, induce alterations in
ERa phosphorylation, and modify receptor action on
genomic and non-genomic targets; (iv) rapid, non-geno-
mic effects through membrane-associated receptors acti-
vating signal transduction pathways such as MAPK and
Akt pathways (i.e. non-genomic action, NGA). Note that
the term, non-genomic effect, is based on the fact that
estrodial signaling pathway doesn’ti n v o l v eE R a itself
(additional file 1) and as a consequence there is no
direct ERa mediated transcription. Furthermore, target
genes can receive input from multiple estrogen actions,
e.g., cyclin D1 is a target of multiple transcription fac-
t o r s( T F ) :S P 1 ,A P 1 ,S T A T 5 ,a n dN F B[ 3 ] .T h e s ef o u r
complex regulatory mechanisms, which describe the dis-
tribution of ERa and co-regulators in the nucleus and
membrane signal transduction proteins, are called topo-
logical mechanisms and instrumental in sustaining
breast cancer growth and progression.
Dynamic gene expression changes characterize the
breast cancer cell response to estrogens, and the kinetics
of ERa target genes are strongly influenced by the hor-
mone treatment times. Early work by Inoue et al. [6]
revealed distinct gene clusters that correspond to either
early or late E2-responsive genes. Frasor and co-workers
[7] defined “early” responsive targets in MCF7 cells as
genes up- or down-regulated by 8 h after E2 treatment;
genes induced by 24 h post E2 treatment were classified
as “late” responders and can be blocked by the protein
translation inhibitor cycloheximide. It was further
demonstrated that cyclin D1 expression was mediated
by the interaction of ERa-Sp1 (early response) and by
MAPK-activated EIk-2 and SRF [3] (later response). As
ERa binding sites are more significantly associated with
E2 up-regulated rather than down-regulated genes [8],
Carroll et al. hypothesized that physiologic squelching is
a primary cause of early down-regulation and late
down-regulation is an ERa-mediated event. Collectively,
these studies and many others [9] strongly support a
temporal mechanism of ERa regulation.
A number of gene regulatory network models have
been developed to integrate ChIP-chip and gene expres-
sion data, including genetic regulatory module algorithm
(GRAM) [10], statistical analysis of network dynamics
(SANDY) [11], Bayesian error analysis model (BEAM)
[12], and two-stage constrained space factor analyses
[13-15]. Although a unified model framework was used
to establish regulatory networks, those computational
approaches were not capable of distinguishing genomic
and non-genomic mechanisms, presumably due to fail-
ure to account for key differences in the type of data
corresponding to genomic and non-genomic mechan-
isms. ERa genomic targets consist of protein binding
signals (ChIP-chip peaks), which is not the case for
non-genomic targets, and thus models and regulation
selection for genomic and non-genomic ERa regulatory
mechanisms are different. In addition, although the
above computational approaches join models for ChIP-
chip and gene expression data, TF motif scans are not
typically performed, making it difficult to infer ERa
DBGA or I-DBGA targets from these approaches.
In this study, we developed a new modulated empiri-
cal Bayes approach to assemble the ERa regulatory net-
work. Our approach, for the first time, differentiates
topological features of ERa regulation mechanisms:
DBGA, I-DBGA, and NGA. By examining the estrogen-
responsive gene network in breast cancer cell models,
we established that the ERa regulatory network changes
over time. This modulated empirical Bayes model con-
trols false positives arising from ChIP-chip binding data,
TF binding site (TFBS) motif scans, and differential
gene expression profiles. Two applications of this regu-
latory network were studied. In the first application, the
agonist/antagonist activities of two active metabolites of
tamoxifen, 4-OH-tamoxifen and endoxifen, were investi-
gated. The second application investigated the impact of
epigenetics (DNA methylation and histone modifica-
tions) on ERa regulatory network in our previously
established breast cancer cell model of acquired tamoxi-
fen resistance [16].
Results
Data analyses overview
The ERa regulatory network model was developed
based on differential gene expression data for MCF7
(untreated, 4 and 24 hour post E2 treatment) [16,17]
and ERa ChIP-chip data [8]. The antagonistic/agonistic
effects of OHT and endoxifen on this network were
assessed using MCF7 gene expression microarray data
a t2 4h o u rp o s tE 2 ,O H T ,e n d o x i f e n ,E 2 + O H T ,a n dE 2
+endoxifen treatments [17]. In MCF7 cells with
acquired resistance to tamoxifen, the response of the
ERa regulatory network was evaluated using gene
expression microarray data [16], and the epigenetic
mechanisms for non-responsive ERa network in MCF7-
T cells were investigated by H3K4me2 and H3K27me3
ChIP-seq data and MCIp-seq.
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Page 2 of 16ERa regulation mechanisms and ERa targets
Based on ERa C h I P - c h i pd a t aa n dm i c r o a r r a ym R N A
expression profiles after E2 stimulation of MCF7 breast
cancer cells, we categorized ERa regulatory mechanisms
into three groups (additional file 2): genomic action
with ERa direct ERE binding (DBGA), genomic action
with ERa indirect/ERE-independent (e.g., AP-1) binding
(I-DBGA), and non-genomic/ligand-independent action
(NGA). In DBGA, the activation of ERa can be either
by E2 (ligand-dependent) or growth factor-mediated
phosphorylation (ligand independent) (additional file 1
and additional file 2). Our current data is not able to
distinguish between these two types of mechanisms.
Different ERa mechanisms and their targets in MCF7
cell are displayed in Figure 1. For the three ERa
mechanisms described above, more up-regulated targets
were observed than down-regulated targets after 4 hour
E2 stimulation (Figure 1A). Both DBGA and NGA
mechanisms have more targets than I-DBGA has. After
24 hour E2 stimulation, a greater (p < 0.00001 vs. 4
hour) number of down-regulated targets was observed
for all three mechanisms (Figure 1B &1C). These results
are not totally consistent with the results in [8], as we
use the 20% fold-change as an additional filtering criter-
ion. Many significantly down-regulated genes have small
fold change, especially after 4 hour E2 treatment.
It is interesting to note that the number of DBGA and
I-DBGA targets at 24 hour was approximately doubled
compared to 4 hour, while an approximate 5-fold
increase in the number of NGA targets was observed at
24 hours (Figure 1A &1B). Furthermore, there was strik-
ingly little overlap among the ERa targets between the
two time points (8.5%, 5.8%, 3.8% for DBGA, I-DBGA,
and NGA) respectively.
Gene ontology enrichment analysis was performed for
the genomic and non-genomic targets at 4 and 24 hour
after E2 stimulation, and the top 5 functional categories
are listed in Table 1 (p-value range for sub-functional
categories is reported for each category). Although both
genomic and non-genomic mechanisms share only a
small number of targets, their functions are highly con-
sistent. At both 4 and 24 hours, genomic targets are
Figure 1 Statistics of ERa targets after E2 stimulation. (A) ERa targets after 4 hour E2 stimulation in MCF7 cells; (B) ERa targets after 24 hour
E2 stimulation in MCF7 cells; (C) Comparisons of up/down-regulated targets within each of three ERa regulation mechanisms; and (D) ERa
targets overlap between 4 and 24 hour after E2 stimulation.
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Page 3 of 16mainly responsible for gene expression, cell morphology,
cellular growth/development/movement, and cell cycle/
death. On the other hand, at both time points, non-
genomic targets are attributed to RNA post-translational
modification, DNA replication/re-combination/repair,
amino acid metabolism, cellular assembly and organiza-
tions. Therefore, genomic and non-genomic mechanisms
have dramatically different impacts on the molecular
and cellular functions in breast cancer cells.
ERa regulatory networks and their hubs
After 4 hours of E2 stimulation, the ERa regulatory net-
work is composed of an ERa hub and multiple inter-
connected hubs (Figure 2A). Both ERa (DBGA) and
Sp1 (I-DBGA) hubs are consistent with genomic
mechanisms, while the other hubs follow non-genomic
mechanisms. The target sizes of genomic and non-geno-
mics hubs are approximately equal; however, after 24
hour of E2 stimulation, there is a pronounced increase
in the number of non-genomic hubs and targets com-
pared to genomic hubs and targets (Figure 2B). These
results demonstrate that while both genomic and non-
genomic hubs are equally important, a greater number
of late response E2 targets are activated through non-
genomic mechanisms compared to genomic hubs. In
addition, a striking feature of this dynamic ERa regula-
tory network is that a consistent set of transcription fac-
tors appear to control the hubs, despite the lack of
overlap for hub targets between the two time points
(discussed above; Figure 1D). These factors include
(ZFP161, TFDP1, NRF1, TFAP2A, EGR1, E2F1, PITX2).
Further comparison of the significant hubs between the
4 and 24 hour networks shows that both statistical sig-
nificance (p-value) and hub size are consistent between
two time points for both genomic and non-genomic
hubs (Figure 3).
Antagonistic/Agonistic effects of tamoxifen metabolites:
4-OH tamoxifen and endoxifen
Different SERMs have been shown to have different
antagonistic/agonistic on E2 up- and down-regulated
genes [18]. The effect of the tamoxifen metabolites
OHT and endoxifen, both well-known SERMS [17], on
ERa target networks has not been compared, particu-
larly with regard to ERa genomic/non-genomic targets.
Among the ERa targets identified after 24 hour of E2
stimulation, 17% and 14% were responsive to OHT and
endoxifen respectively, with 74% of the targets overlap-
ping (additional file 3). The agonist, antagonist, and par-
tial agonist/antagonist activity of OHT and endoxifen on
the ERa targets at 24 hour post E2 stimulation were
nearly identical for the two SERMS (41%, 7%, 52% and
40%, 7%, 53% for OHT and endoxifen, respectively;
additional file 4).
We further classified the effects of OHT and endoxi-
fen on ERa genomic/non-genomic and up/down regula-
tion. There was a tendency for a greater agonistic effect
on ERa genomic targets than non-genomic targets after
E2 or OHT treatment (p = 0.01; Figure 4A). However,
this difference in agonistic activity on genomic/non-
genomic targets was not seen (p = 0.67, Figure 4B) after
E2 or endoxifen treatment.
Epigenetic modifications impact the ERa regulatory
network in tamoxifen resistant MCF7 cells
Breast cancer cell models for acquired resistance to
tamoxifen display progressive loss of estrogen-dependent
signaling for cell growth and proliferation and a
Table 1 Gene Ontology Analysis of Estrogen Targets
ERa Target
Mechanism
4 hour after E2 Stimulation 24 hour after E2 Stimulation
Functional Category P-value
Range
N Functional Category P-value
Range
N
Genomic Gene Expression 2E-6 - 9E-3 26 Cellular Growth 4E-7 - 1E-2 96
Cell Morphology 4E-6 - 1E-2 15 Cell Cycle 2E-6 - 1E-2 37
Cellular Growth 3E-5 - 1E-2 37 Cell Death 4E-5 - 1E-2 70
Cellular Development 5E-5 - 1E-2 22 Cellular Movement 5E-5 - 1E-2 46
Cell Cycle 1E-4 - 1E-2 21 Cellular Development 6E-5 - 1E-2 48
Non-genomic RNA Post-Transcription 5E-6 - 4E-2 5 DNA Replication, Recombination, and
Repair
1E-9 - 3E-2 62
Modification
Cellular Development 8E-4 - 5E-2 2 Cell Cycle 1E-9 - 3E-2 70
DNA Replication, Re-combination, and
Repair
1E-3 - 4E-2 6 RNA Post-Transcription Modification 6E-6 - 2E-2 16
Cellular Growth 1E-3 - 4E-2 8 Post-Transcription 5E-4 - 3E-2 15
Amino Acid Metabolism 5E-3 - 5E-2 2 Modification Cellular Assembly and
Organization
6E-4 - 3E-2 37
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Page 4 of 16disrupted ERa regulatory network [16]. Among the ERa
targets observed after 4 hour E2 stimulation of MCF7,
only one target remained hormone responsive in the
tamoxifen-resistant MCF7-T subline (NRF1; Figure 5).
In order to understand the role of epigenetics in this non-
responsive ERa network, we investigated five possible
mechanisms (additional file 5): (A) high basal gene expres-
sion in the MCF7-T cell; (B) hypermethylation (MCF7-T
Figure 2 ERa regulatory network after E2 stimulation. (A) ERa regulatory network after 4 hours E2 stimulation in MCF7 cells; and (B) ERa
regulatory network after 24 hours E2 stimulation in MCF7 cells.
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high methylation level in MCF7-T; and (C) high H3K27/
H3K4 ratio. As shown in Figure 6, these mechanisms
account for approximately 27%, 19%, 15%, 34%, and 22%
of the non-responsive targets (Figure 6A); however, these
five mechanisms are not able to account for approx. 28%
of targets. Substantial (36%) overlap was seen between
hypermethylation (mechanism 2) and high basal methyla-
tion in MCF7-T cell (mechanism 4) (Figure 6B).
Validation studies
Pol II-Binding. We compared PolII binding signals in
MCF7 before and after 4 hour E2 stimulation. Nearly all
ERa genomic targets displayed the same direction in
fold-change between PolII binding and gene expression
signals (98%; additional file 6A). Among the non-geno-
mic targets, this concordance rate dropped slightly
(86%). On the other hand, the concordance rate among
non-targets was 55%.
H3K4 Dimethylation is a well established histone mar-
ker for transcription activation acetylation marker. We
selected the median of H3K4 dimethylation ChIP-seq
signal as the threshold. Almost all ERa genomic targets
displayed H3K4 dimethylation higher than the median
(94%, additional file 6B). Among the non-genomic tar-
gets, this concordance rate dropped slightly (84%). On
the other hand, the concordance rate among non-targets
was 49%.
Figure 3 Regularory hubs in ERa regulatory network. (A) The correlation of the significance of hubs between 4 hour and 24 networks; and
(B) The correlation of the significance of non-genomic hubs between 4 hour and 24 networks. Both axis are the -log(p-value), and the width
and length of the squares represent the relative scales of hubs.
Figure 4 Effect of selective ERa modulators. (A) The agonistic effect of 4-OH tamoxifen is greater on genomic mechanism than on
antagonistic or partial effects (p = 0.01). (B) No evidence for agonistic, antagonistic, or partial effects of endoxifen on genomic or non-genomics
mechanisms.
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MCF7 Cell We used a different data set by Cicatiello et
al. [19], in which MCF7 cells were treated with E2, and
sampled at baseline, 4 hr and 24 hr. This experiment
was performed on a different gene expression platform,
Illunima. We applied a similar empirical Bayes model
and the same fold change threshold. We obtained a
similar percentage of up/down regulated genes after 4h/
24h estrogen treatment. In addition, the overlap of 4
and 24 hour gene targets was, 7%, similar to what we
found out with our data.
RT-qPCR, ChIP-PCR, and COBRA. We further investi-
gated four types of epigenetics mechanisms.
￿ Mechanism 1: GAB2 and LAMB2 were non-
responsive in our network due to significantly
increased basal expression in MCF7-T vs.M C F 7
(based on microarray data). Although RT-qPCR ana-
lysis confirmed that GAB2 and LAMB2 expression
was significantly higher in MCF7-T vs.M C F 7( F i g -
ure 7A,B), both genes were slightly responsive to E2
in MCF7-T. Our interpretation is that Affymetrix
technology can be saturated for highly expressed
genes, becoming insensitive to subtle expression
changes. Nonetheless, the non-responsive mechan-
ism needs further experimental investigation.
￿ Mechanism 5: PGR, PLS3, SPATA13, GREB1, and
MAOA were non-responsive because of a high ratio
of H3K27me3:H3K4me2 in MCF7-T vs.M C F 7 .
Using ChIP-PCR, this mechanism was validated in
four of five target genes (Figure 7C,D,F,G; exception
was SPATA13, Figure 7E).
￿ Mechanisms 2 and 4: the DNA methylation status
four ERa t a r g e t s( P G R ,P L S 3 ,C R E B 1 ,S P A T A 1 3 )
was examined. Using COBRA assays, increased
DNA methylation was observed in PGR and PLS3
in MCF7-T compared to MCF7 (Figure 7H;
mechanism 4), and increased methylation in the
MCF7-T and the MCF7 (mechanism 2). Further-
more, in the non-responsive ERa network, both
PGR and PLS3 displayed both repressive epigenetic
modifcations, the altered histone methylation ratio
(mechanism 5) and altered DNA methylation
(mechanism 2 and 4).
Figure 5 ERa regulatory network in drug-resistant cells.E R a regulatory network in MCF7 cell after 4 hour E2 stimulation becomes non-
responsive to E2 in the MCF7-T cell (only one target gene remains responsive).
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Advantage of the modulated empirical bayes method in
assembling a TF regulatory network model
Our proposed ERa regulatory network model frame-
work differs from existing methods in its ability to dis-
tinguish between genomic and non-genomic actions,
and the assumption for functional TFs. The pioneer TF
regulatory network for Saccharomyces cerevisiae, devel-
oped by Luscombe et al. [11] and Lee et al. [20],
emphasized that TFs themselves should be highly
expressed and display differences in expression level.
However, these assumptions tend to be overly stringent
and not suitable for our data. Our gene expression
microarray data suggested that the majority of the TFs
(more than 70%) are expressed at low levels in MCF7
cells, and E2 stimulation results primarily in changes in
TF phosphorylation state and not robust changes in TF
expression in breast cancer cell lines, including MCF7
[7,16,21]. All of the TFs in our genomic and non-geno-
mic hubs didn’t change their expression significantly
(additional file 7 and additional file 8). Stringent statisti-
cal models have recently been developed to establish TF
regulatory networks [12,13,15]. Such regression-based
approaches were not significant when used to analyze
our data (not even for ERa itself), mainly due to the
fact that TFs, including ERa, have both up- and down-
regulated targets. If targets that change in opposite
directions are not treated differently, the regression
model will cancel-out any effect of a TF on gene expres-
sion. Therefore, regression model-based approaches to
identify TF regulatory networks can be sensitive to a
mis-specified model.
Our proposed empirical Bayes method modulates FDR
calculations from differential gene expression data,
ChIP-chip binding peaks, and TF motif scans. The
inferred ERa regulatory network model has the follow-
ing features and advantages:
￿ Distinct genomic and non-genomic mechanisms.
￿ Less stringent requirements on TF gene expression
levels.
￿ Modulated data analysis leading to robust conclu-
sions with respect to model misspecifications.
￿ Modulated model assembly results in an extend-
able TF network, which is particularly useful when
additional data becomes available for new molecular
mechanisms.
ERa regulatory network and corresponding hubs
When constructing genomic targets of the ERa regula-
tory network, TFs are scanned within a narrow region,
45bp, of ERa ChIP-chip binding sites. This calculation
scheme enables the identification of either DBGA or
indirect I-DBGA. In many previous studies [8,22-24],
relatively large neighborhoods surrounding the ERa
binding site (around 500~1000bp) were scanned for
consensus sequences of TFBSs. While this is an effective
strategy for identifying co-regulatory TFs, it is not an
effective approach for inferences regarding DBGA or I-
DBGA. For example, Lin et al. [23] demonstrated that
EREs and ERE half-sites were enriched for other tran-
scription factors motifs, supporting the notion that TFs,
in addition to ERa, can bind to ERE. In our analysis, we
identified only Sp-1 as an I-DBGA. Although AP1 has
been reported to be an I-DBGA, in our data it did not
pass the false positive threshold (FDR = 0.23), due to its
relatively short TFBS (6 bp). Binding motifs for forkhead
TFs have also been reported to be enriched within ERa
Figure 6 Epigenetic mechanisms in drug-resistant cells.
Epigenetic mechanisms in ERa regulatory network in MCF7-T cell: 1
high basal gene expression in MCF7-T cells; 2 hypermethylation
from MCF7 cells to MCF7-T cells; 3 hypomethylation from MCF7
cells to MCF7-H cells; 4 high basal methylation level in the MCF-T
cells; 5 high H3K27/H3K4 ratio; and 6 unknown mechanisms. (A) The
distribution of non-responsive mechanisms in ERa regulatory
network in MCF7-T cell. (B) The overlap among 5 non-responsive
mechanisms.
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Page 8 of 16binding regions in MCF7 cells by ChIP-chip [8]. How-
ever, in our study, there was not sufficient evidence to
support FoxA1 as an I-DBGA (FDR = 0.34), a result
supported by recent studies using ChIP-seq and ChIP-
D S L[ 2 5 - 2 7 ] .R e c e n t l y ,R A Ra n dE R a binding were
shown to be highly coincident throughout the genome,
competing for binding to the same or similar response
elements [28]. Our ERa regulatory network model, how-
ever, is not able to identify RAR targets, as the ChIP-
chip experiments were only performed for ERa binding
sites and not RAR.
In our analysis, non-genomic targets of the ERa regu-
latory network were constructed using genes whose pro-
moters, introns, or downstream sequences were devoid
of ERa ChIP-chip binding sites. Significant TF scan
scores of these gene promoters infer ERa non-genomic
action (NGA). It is worth noting that these NGA differ
from previously described ERa co-regulator factors.
NGA does not require ERa binding, in contrast to ERa
co-regulatory factors which must display ERa binding
peaks in the ChIP-chip analysis. Significant NGA tran-
scription factors include ZFP161, TFDP1, NRF1,
TFAP2A, EGR1, E2F1, and PITX2 (p <0.01). Other sig-
nificant NGA includes MYC, which has been previously
reported [28], and although MYC was present in both 4
and 24 hour ERa regulatory networks, the level of sig-
nificance was not high enough to be considered a hub
(p = 0.14).
Among the nine hubs that are significantly enriched in
both 4 hour and 24 hour ERa networks, two facilitate
genomic activities (ERa and Sp1), while the other seven
hubs (ZFP161, TFDP1, NRF1, TFAP2A, EGR1, E2F1,
PITX2) mediate non-genomic actions. With the excep-
tion of (ZFP161, TFDP1, PITX2), the functions of (Sp1,
NRF1, E2F1, TFAP2A, EGR-1) and their functional rele-
vance to estrogen action in breast cancer cells have
been extensively documented in [29-32].
While the ERa regulatory network concept has
recently been reviewed [33,34], our study is the first to
characterize genomic and non-genomic mechanisms and
their different functions. The genomic mechanism is sig-
nificantly involved in cell proliferation and control of
cell phases, confirming a significant effect of estrogen
on cell cycle regulation. Biological processes significantly
Figure 7 RT-PCR, ChIP-PCR and COBRA Validations
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Page 9 of 16affected by the non-genomic mechanism include RNA
post-translation modification, cellular development,
DNA replication, re-combination, and repair. Additional
models describing network properties of estrogen signal-
ing targets include the protein-protein interaction and
the functional module networks [28]. The focus of the
two networks is on the functional interpretation of the
targets and not mechanism of regulation. Furthermore,
the edges are interpreted as either protein interaction or
functional similarity and are not directional, compared
to the edges in our regulatory network, which have up
or down-regulation direction.
Antagonist/agonist effects of SERMs on ERa regulatory
networks
We observed full and partial antagonist/agonist effect of
OHT on MCF7 after 24 hour E2 stimulation, similar to a
previous study [18]. We further show that genomic and
non-genomic actions of the ERa regulatory network are
differentially influenced by full or partial antagonist/ago-
nist activities of OHT and endoxifen. The current study
clearly demonstrates that the E2 responsive ERa regula-
tory network is disrupted by two SERMs (additional file
4), but whether new networks are stimulated by these or
other SERMs require additional investigation.
Epigenetic Modifications of ERa Regulatory Network in
the MCF7-T Cell
A second application of the regulatory network was to
examine the impact of epigenetics (DNA methylation
and histone modifications) on the ERa regulatory net-
work in a breast cancer cell model for acquired tamoxi-
fen resistance of [16]. Transcriptionally active genes are
typically marked by higher levels of di-/tri-methylated
H3K4 (H3K4me2/3) and low trimethylated H3 lysine 27
(H3K27me3) levels [35], and in hormone responsive
MCF7 cells, E2-stimulated target genes have been
shown to posses enriched regions of H3K4me1/2 [36].
In contrast, MCF7 with acquired tamoxifen resistance
(MCF7-T), groups of previously E2-responsive genes are
now associated with low H3K4me2 and high H3K27me3
and are either downregulated or no longer strongly hor-
mone inducible (Figure 8). The H3K27me3 mark is
stable and invariably associated with transcriptional
repression [37,38] and we show that this repressive his-
tone modification plays a key role in the unresponsive
ERa regulatory network in MCF7 cells with acquired
resistance to tamoxifen (Figure 8). Although tumori-
genic gene silencing mediated by H3K27me3 has been
shown to occur in the absence of DNA methylation
[38,39], repressive histone marks frequently coordinate
with the more permanent mark of DNA methylation in
heterochromatin [39-41]. We previously demonstrated
that alterations in DNA methylation play an important
role in acquired tamoxifen resistance [16]. By integrating
both repressive epigenetic marks into our model, we
demonstrate that H3K27me3 and DNA methylation sig-
nificantly contribute to the non-responsive ERa regula-
tory network model in tamoxifen resistant breast cancer.
Furthermore, having recently demonstrated that many
TFBSs are enriched in regions of altered DNA methyla-
tion [42], we suggest that the functions of activators or
repressors could be altered by changes to the DNA
methylation landscape and further impact ERa networks
in breast cancer, an active area of investigation in our
laboratory.
When we compare the percentages of different epige-
netic mechanisms (Figure 7, 27%, 19%, 15%, 34%, 22%),
to 20% each for a random gene set based on the
selected thresholds, it seems that the non-responsive
targets have similar distribution of various types of epi-
genetic mechanisms as that of a random gene set.
Therefore, it is possible that there may not exist specific
patterns of epigenetic mechanisms in MCF7 cells’
acquired tamoxifen resistance.
Conclusions
In breast cancer cells, we identified a number of estro-
gen regulated target genes and the estrogen-regulated
network that characterizes the causal relationships
between transcription factors and their targets. This net-
work has two major mechanisms, the genomic action
and the non-genomic action. In genomic action, after
estrogen receptor is activated by estrogen, estrogen
receptor regulated genes through directing binding to
DNA. In non-genomic action, estrogen regulated its
gene targets through non-direct binding through other
factors. In the estrogen regulated network, we found
that though many non-genomic targets change over
time, they do share many common factors and the con-
sistency is highly significant. Moreover, we found that
many gene targets of this network were not active any-
more in anti-estrogen resistant cell lines, possibly
because their DNA methylation and histone acetylation
patterns have changed. Taken together, our model has
revealed novel and unexpected features of estrogen-
regulated transcriptional networks in hormone respon-
sive and anti-estrogen resistant human breast cancer.
Methods
Chromatin immunoprecipitation and ChIP-Seq library
generation
Chromatin immunoprecipitation (ChIP) for PoI II (sc-
899X, Santa Cruz, CA), H3K4me2 (Millipore, 07-030,
Billerica, MA) and H3K27me3 (Diagenode, CS-069-100,
Sparta, NJ) was performed as previously described [43].
ChIP libraries for sequencing were prepared following
standard protocols from Illumina (San Diego, CA) as
Shen et al. BMC Systems Biology 2011, 5:67
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Page 10 of 16described in [44]. ChIP-seq libraries were sequenced
using the Illumina Genome Analyzer II (GA II) as per
manufacturer’s instructions. Sequencing was performed
up to 36 cycles for mapping to the human genome
reference sequence. Image analysis and base calling were
performed with the standard Illumina pipeline, and with
automated matrix and phasing calculations on the PhiX
control that was run in the eighth lane of each flow-cell.
Samples were run on duplicates.
Methyl-CpG immunoprecipitation (MCIp-seq)
MCIp-seq was performed and followed the manufac-
ture’s protocol (MethylMiner, Invitrogen, Carlsbad, CA).
Briefly, genomic DNA was sheared by sonication into
Figure 8 Flow-Chat of ERa Regulatory Network Construction
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Page 11 of 16200-600-bp fragments, and methylated DNA was
immuno-precipitated by incubating 1 μg of sonicated
g e n o m i cD N Af o r1 ha tr o o mt e m p e r a t u r ew i t h3 . 5μg
of recombinant MBD-biotin protein and Streptavidin
beads. Methylated DNA was eluted with high-salt buf-
fers (500 or 1,000 mmol/L NaCl), and then recovered by
standard phenol chloroform procedure. The DNA frac-
tions were subjected to library generation and followed
by Illumina sequencing. Samples were run in duplicate.
Quantitative ChIP-PCR
To determine binding levels of H3K4me2 and
H3K27me3 on target genes, quantitative ChIP-PCR was
used to measure the amount of this sequence in anti-
H3K4me2 or H3K27me3-immunoprecipitated samples
by PCR with SYBR Green-based detection (Applied Bio-
systems). Experimental quantitative ChIP-PCR values
were normalized against values obtained by a standard
curve (10-fold dilution, R
2>0.99) constructed by input
DNA with the same primer set. Specific primers for
amplification are available upon request.
Reverse transcription and quantitative PCR (RT-qPCR)
Total RNA (1 μg) was reverse transcribed with the
Superscript III reverse transcriptase (Invitrogen, Carls-
bad, CA). PCR was performed as described previously
[45]. Specific primers for amplification are available
upon request. The relative cellular expression of a cod-
ing gene was determined by comparing the threshold
cycle (Ct) of the gene against the Ct of GAPDH.
Identification of differentially expressed genes and FDR
calculation
An empirical Bayes approach in the mixture-model fra-
mework was developed to assess differential gene
expression data from Affymetrix platform. Because the
differential expression inference is made at the gene
level rather than at the probe level, our model is an
extension of Kendziorski’sw o r k[ 4 6 , 4 7 ] .I nt h i sm o d e l ,
between-gene variation, between-probe variation and
between replicate are included. Specifically, let i index
genes (i = 1.2.,...,I), l index conditions/groups/time (l =
1,2; 1 is the reference), j index probe set (j = 1,2,..., ni)
and k index replicate (k = 1,2,..., mi). Let Gijk be the
expression level of the kth replicate on probe j for gene
i under group l. We consider the following random-
effects model:
Gijkl = μil + bij + εijkl
bij ∼i.i.d. N(0,σ2
i ), εijkl ∼i.i.d. N(0,δ2
ijl)
(1)
where μil is the gene expression level for gene i under
condition l,bij represents the probe effect for the jth
probe of gene i and εijkl is the error term (for genes
with only one probe, the probe effect b is eliminated
from model (1)). We consider that the genes come from
three latent populations, each of which is characterized
by the location of μij (X variable) and μi2 (Y variable) on
a two-dimensional plane. The first population, a bivari-
ate normal distribution with the center located above
the y = x line, represents up-regulated genes. The sec-
ond population, a normal distribution along y = x line,
represents unchanged genes. The third population, a
bivariate normal distribution with the center below the
y = x line, characterizes down-regulated genes. Denote
by Yi a latent indicator such that Yi = 1,0,-1 implies that
gene i belongs to the first, second and third populations,
respectively. Thus, we consider the following model for
μil:

μi =( μi1,μi2)|Yi

= f
I(Yi=1)
1 f
I(Yi=0)
0 f
I(Yi=−1)
−1 ,
f1 = BN(μi;η1, 1),
f0 = I(μi1 = μi2)N(μi1;λ,φ2),
f−1 = BN(μi;η−1, −1),
Pr[Yi =1 ]=ρ1;P r [ Yi = −1] = ρ−1;P r [ Yi =0 ]=ρ0,
η12 > η11,ξ12 <ξ 11,ρ1 + ρ−1 + ρ0 =1 ,
(2)
where I(.) is a function that takes value 1 if the argu-
ment is logical/true and 0 if otherwise; BN and N
denote the bivariate and univariate normal distributions,
respectively. By integrating equations (1) and (2), one
can use the Expectation-Maximization (EM) algorithm
(S1.doc) to estimate the parameter vector θ =( r, h1, Σ1,
h-1, Σ-1,l,,s,δ). The posterior probability Pr[Yi =0 |G, ˆ θ]
can be interpreted as the probability that gene i is not
differentiated. Rigorously speaking, Pr[Yi = ±1|G, ˆ θ] can-
not be directly interpreted as the probability that gene i
is up/downregulated. However, a probability close to 1
indicates a good approximation. In our analysis, we
claim that a gene is up-regulated if Pr[Yi =1 |G, ˆ θ] > c
and ˆ μi2 −ˆ μi1 > 0 or downregulated if
Pr[Yi = −1|G, ˆ θ] > c and ˆ μi2 −ˆ μi1 < 0. The local FDR
can be easily estimated by 1 − Pr[Yi =1 |G, ˆ θ] or
1 − Pr[Yi = −1|G, ˆ θ][48]. In our analysis, we set c = 0.80.
Models (1) and (2) are fitted to baseline and E2 stimu-
lated (4 and 24 hours) expression data for MCF7 cells.
In addition to FDR, we also set 20% fold-change in
either up- or down-regulation in expression as the bio-
logically significant effect size. Binding Scores for Peak
Areas Identified by ChIP-chip and FDR Calculation is
based on model-based analysis of tiling-arrays [49].
Motif binding site scan and FDR calculation
Genomic Binding Sites: Each significant ChIP-chip peak
binding site sequence of length 45 bp (25 bp of tiling
array probes plus 10 bp up/downstream of each probe)
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Page 12 of 16is scanned by all of the TF motifs in TRANSFAC data-
bases. The range of binding scores for a transcription
factor with motif M are divided into a number of small
bins (k = 200). The number of scores fall into each bin
is then calculated. If the number of any bin is lower
than a pre-specified limit (t = mb 20), the bin is col-
lapsed with neighboring bins until the number is beyond
the limit. The number of scores that fall in each bin is
denoted b by mb. Then, we randomly generate R =
10,000 sequences based on human genome background
using a 6
th order Markov model. This model assumes
that a sequence element probability depends on 6 pre-
vious bases, immediately preceding the current base
[50]. The binding scores for these random sequences
are calculated, and the number of scores that falls into
each bin is denoted by nb. Finally, the local FDR, in
terms of binding event for scores in bin b, is calculated
as
FDRb,M =
nb/R
mb/I
, (3)
where I is the total number of genes. In doing so, we
force the bins below the midpoint of the score range to
have FDRb,m = 1 because it is highly unlikely that these
low score bins represent true binding events. Finally, we
fit a cubic smoothing-spline to FDRb,m to get FDRs,m,
the local FDR at score s (degree = 4, # of knots = # of
unique FDRb,m values). Then for each gene, we have the
FDR estimate respect to the event that TF g binds to
gene i’s promoter. This non-parametric approach to
estimate FDR was first described by Efron et al. [51] in
differential gene expression data analysis.
Non-genomic Binding Sites: We applied the same
method as above to the motif binding scores collected
from each gene promoter upstream 1Kb.
Modulated empirical bayes model: DBGA, I-DBGA, and
NGA mechanism determination based on ChIP-chip peak,
TF motif scan and differential gene expression data
Based on FDRs calculated from empirical Bayes models
in differential gene expression, ChIP-chip binding peaks,
and TF motif scan scores, DBGA, I-DBGA, and NGA
targets were calculated using the flow-chart displayed in
Figure 8. Graphical interpretations of different mechan-
isms and their associated data types are displayed in Fig-
ures S1 and S2. In brief, both genomic and non-genomic
targets must have significantly differentially expressed
genes, while only genomic targets have significant ChIP-
chip binding peaks. Finally, a DBGA has a significant
ERa motif in the ChIP-chip binding sites, an I-DBGA
has one or more significant TF motifs (other than ERa)
in the ChIP-chip binding sites, and a NGA has one or
more significant TF motifs in its target gene promoter.
TF Hub significance calculation
To quantify the significance of well-connected TF hubs,
we consider the following null hypothesis: TFs that are
involved in the regulation of differential genes are ran-
domly picked from a pool of known TFs. Specifically, we
suppose there are M differential genes. For each gene i,
there are bi binding sites by ChIP-chip and motif search
that pass the threshold, which involve ni (ni ≤ bi) unique
TFs. Therefore, there are a total of N =
M 
i=1
ni involved
TFs. If there are n known TFs, then under the null
hypothesis the number of connected nodes for each TF is
the same as the number of times each TF appear from M
random draws with each draw of size ni. Note that each
draw of ni is without replacement because they represent
distinct transcription factors. The distribution of the
number of connected nodes (T) for any TF is
Pr(T = t)=

ω∈ (t)


i∈ω

n − 1
ni − 1


i/ ∈ω

n − 1
ni

M 
i=1

n
ni
 ,(4)
where Ω(t) is the set of all subsets of {1,2,...,M}w i t ht
elements. Hence, p-values associated with hub TFs can
be obtained by calculating Pr(T ≥ tobs), where tobs is the
observed number of genes regulated by the TF of inter-
est. This calculation is programmed in R.
Signal identification for ChIP-seq (PolII, H3K4me2,
H3K27me3) and MCIp-seq
In order to evaluate transcriptional activity, activating
and repressive histone methylation marks, and DNA
methylation of ERa target genes, ChIP-seq data for
RNA Pol II, H3K4me2, and H3K27me3 and MIRA-seq
data DNA methylation were analyzed. Total sequences
were normalized among replicates. For the ChIP-seq
data, the signal intensity was measured as the number
of ChIP-seq tags within the promoter region, defined as
1,000-bp upstream of TSS (transcription start site). In
the MCIp-seq data, seq tags within upstream 1000bp
and downstream 1000bp of the TSS were selected for
promoter DNA-methylation.
Identifications of agonist, antagonist, and partial agonist/
antagonist selective estrogen receptor modulator (SERM)
targets
Let (FCE2, FCSERM, FCE2+SERM) be the fold-change of
gene expression after treatment of MCF7 cells with E2,
SERM (OHT or endoxifen), or E2+SERM). We defined
f o l d - c h a n g ea sg e n ee x p r e s s i o ni nt h et r e a t m e n tg r o u p
over the control group for up-regulation; otherwise, it is
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gene is absent in both groups, the fold-change is defined
as 1. A SERM has an agonistic effect on a gene if |
FCSERM|>[ 1+7 0 %×( | FCE2| - 1)], an antagonistic
effect if |FCSERM| < [1 + 35% × (|FCE2|-1 ) ]a n d| FCE2
+SERM|<[ 1+5 0 %×( | FCE2| - 1)]; otherwise, it has a
partial agonistic/antagonistic effect. These agonist and
antagonist activities have been defined previously [18].
Epigenetic mechanisms of non-responsive ERa network in
4-hydroxy tamoxifen (OHT) resistant MCF7 cells
For ERa targets in the ERa regulatory network 4 hours
after E2 stimulation, five different epigenetic mechan-
isms were investigated (additional file 5).
￿ The first mechanism (additional file 5A) is the
high-basal gene expression in the 4-OHT-resistant
MCF7 cells, in which the threshold of high-basal
gene expression is defined as its 80
th percentile.
￿ The second mechanism (additional file 5B) is
defined as the hyper-methylation: i.e., higher methy-
lation level of OHT-resistant MCF7 than the paren-
tal (hormone-responsive) MCF7. The threshold of
this fold-change is defined as its 80
th percentile.
￿ The third mechanism (additional file 5C) is defined
as the hypo-methylation: i.e., lower methylation level
of OHT-resistant MCF7 vs. MCF7. The threshold of
this fold-change is defined as its 80
th percentile.
￿ The fourth mechanism (additional file 5D) is
defined as the high methylation in the OHT-resis-
tant MCF7. The threshold of methylation level is
defined as its 80
th percentile.
￿ The fifth mechanism (additional file 5E) is defined
a st h eh i g hH 3 K 2 7 / K 3 K 4r a t i o ,ag e n er e p r e s s i v e
mark, in the OHT-resistant MCF7. The threshold of
this ratio level is defined as its 80
th percentile.
All other non-responsive ERa targets were categorized
as “unknown”.
Additional material
Additional file 1: is a jpeg file, indicating the situations of ligand-
dependent genomic target, ligand-independent genomic target and
non-genomic target
Additional file 2: is a jpeg file, indicating the relationships between
data and ERa mechanisms
Additional file 3: is a jpeg file, indicating the effect of 4OH-
tamoxifen and endoxifen on the network
Additional file 4: is a jpeg file, indicating agonistic, antagonist, and
partial agonistic/antagonistic effects of 4-OH-tamoxifen and
endoxifen
Additional file 5: is a jpeg file, indicating non-responsive
mechanisms in ERa regulatory network in MCF7-T cell. (A) high basal
gene expression in MCF7-T cells; (B) hypermethylation from MCF7 cells
to MCF7-T cells; (C) hypomethylation from MCF7 cells to MCF7-H cells;
(D) high basal methylation level in the MCF-T cells; (E) high H3K27/H3K4
ratio.
Additional file 6: is a jpeg file, indicating the concordance between
differential PolII bindings and differential gene expression among
genomic-targets, non-genomic targets, and none targets; and the
concordance between H3K4 dimethylation among genomic-targets,
non-genomic targets, and none targets. (A) The concordance of
differential gene expression and PolII binding are before and after E2
stimulation of MCF7 cells. (B) The concordance of differential gene
expression and H3K4 dimethylation.
Additional file 7: Supplementary Table 1
Additional file 8: Supplementary Table 2
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elements; TFBS: TF binding site; EM: Expectation-Maximization;
Acknowledgements
This work is supported by the U.S. National Institutes of Health grants R01
GM74217 (L. L.), AA017941 (Y.L.), CA113001 (T.H-M.H. and K.P.N), Department
of Defense (DOD) BC030400 (C.S.), China 863 High-Tech Program
2007AA02Z302 (Y.L.), R01 GM088076 (T.S.), U-01 GM61373 (D.F.) and China
Natural Science Foundation 60901075 (G.W.).
Author details
1Center for Computational Biology, Indiana University School of Medicine,
Indianapolis, IN 46202, USA.
2Division of Biostatistics, Indiana University
School of Medicine, Indianapolis, IN 46202, USA.
3Department of Medical
and Molecular Genetics, Indiana University School of Medicine, Indianapolis,
IN 46202, USA.
4Division of Clinical Pharmacology, Indiana University School
of Medicine, Indianapolis, IN 46202, USA.
5Indiana University Melvin and Bren
Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN
46202, USA.
6Center for Medical Genomics, Indiana University School of
Medicine, Indianapolis, IN 46202, USA.
7Departments of Cellular and
Integrative Physiology, Indiana University School of Medicine, Indianapolis, IN
46202, USA.
8School of Computer Science and Technology, Harbin Institute
of Technology, Harbin, Heilongjiang, 150001, China.
9Information and
Computer Engineering College, Northeast Forestry University, Harbin,
Heilongjiang, 150001, China.
10Division of Human Cancer Genetics, Ohio
State University, Columbus, OH, 43210, USA.
11Department of Molecular
Virology, Immunology, and Medical Genetics, Ohio State University,
Columbus, OH, 43210, USA.
12Comprehensive Cancer Center, Ohio State
University, Columbus, OH, 43210, USA.
13Medical Sciences, Indiana University
School of Medicine, Bloomington, IN, 47405, USA.
Authors’ contributions
CS designed part of the computational study, implemented the empirical
Beyes model and drafted part of the manuscript. YH designed the validation
study, conducted the experiments to validate the computational model, and
drafted part of the manuscript. YL designed part of the computational study,
implemented part of the analysis of ChIP-chip data and motif search, and
drafted part of the manuscript. GW, YZ, ZW and MT implemented part of
the analysis of ChIP-chip data and motif search and drafted part of the
manuscript. YW, DF and TS provided critical guidance on the computational
and experimental elements of the study and made critical revision of the
manuscript. PY carried out part of validation experiments and revised the
manuscript, KN and TH provided biological guidance on the interpretation
of the computational model and design of the validation experiments, and
drafted part of the manuscript. LL conceived the overall design of the study,
drafted most part of the manuscript, and provided both statistical and
biological input for the development and validation of the computational
model. All authors read and approved the final manuscript.
Received: 24 November 2010 Accepted: 9 May 2011
Published: 9 May 2011
Shen et al. BMC Systems Biology 2011, 5:67
http://www.biomedcentral.com/1752-0509/5/67
Page 14 of 16References
1. McDonnell DP, Norris JD: Connections and regulation of the human
estrogen receptor. Science 2002, 296:1642-1644.
2. Ali S, Coombes RC: Estrogen receptor alpha in human breast cancer:
occurence and significance. Journal of Mammary Gland Biologic Neoplasia
2000, 5:271-281.
3. Bjormstrom L, Sjoberg M: Mechanisms of estrogen receptor signaling:
convergence of genomic and non-genomic actions on target genes.
Molecular Endocrinology 2005, 19(4):833-842.
4. DeNardo DG, Kim H, Hilsenbeck S, Cuba V, Tsimelzon A, Brown P: Global
gene expression analysis of estrogen receptor transcription factor cross
talk in breast cancer: identification of estrogen-induced/activator
protein-1-dependent genes. Molecular Endocrinology 2005, 19(2):362-378.
5. Hall JM, Couse JF, Korach KS: The multifaceted mechanisms of estradiol
and estrogen receptor signaling. The Journal of Biological Chemistry 2001,
276:36869-36872.
6. Inoue A, Yoshida N, Omoto Y, Oguchi S, Yamori T, Kiyama R, Hayashi S:
Development of cDNA microarray for expression profiling of estrogen-
responsive genes. Journal of Molecular Endocrinology 2002, 29:175-192.
7. Frasor J, Danes JM, Komm B, Chang KCN, Lyttle R, Katzenellenbogen BS:
Profiling of estrogen up- and down-regulated gene expression in
human breast cancer cells: insights into gene networks and pathways
underlying estrogenic control of proliferation and cell phenotype.
Endocrinology 2003, 144:4562-4574.
8. Carroll JSMC, Song J, Li W, Geistlinger TR, Eeckhoute J, Brodsky AS,
Keeton EK, Fertuck KC, Hall GF, Wang Q, Bekiranov S, Sementchenko V,
Fox EA, Silver PA, Gingeras TR, Liu XS, Brown M: Genome-wide analysis of
estrogen receptor binding sites. Nature Genetics 2006, 38:1289-1297.
9. Cheung EKW: Genomic analyses of hormone signaling and gene
regulation. Annu Rev Physiol 2010, 72:191-218.
10. Bar-Joseph ZGG, Lee TI, Rinaldi NJ, Yoo JY, Robert F, Gordon DB, Fraenkel E,
Jaakkola TS, Young RA, Gifford DK: Computational discovery of gene
modules and regulatory networks. Nature Biotechnology 2003,
21:1337-1342.
11. Luscombe NM, Babu MM, Yu H, Snyder M, Teichmann SA, Gerstein M:
Genomic analysis of regulatory network dynamics reveals large
topological changes. Nature 2004, 431:308-312.
12. Sun NCR, Zhao H: Bayesian error analysis model for reconstructing
transcriptional regulatory networks. PNAS 2006, 103:7988-7993.
13. Yu T, Li KC: Inference of transcriptional regulatory network by two-stage
constrained space factor analysis. Bioinformatics 2005, 21:4033-4038.
14. Xing B, van der Laan M: A causal inference approach for constructing
transcriptional regulatory networks. Bioinformatics 2005, 21:4007-4013.
15. Xing B, van der Laan M: A statistical method for constructing
transcriptional regulatory networks using gene expression and sequence
data. Journal of Computational Biology 2005, 12:229-246.
16. Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer SL, Salisbury JD,
Cheng AS, Li L, Abbosh PH, Huang TH, Nephew KP: Diverse gene
expression and DNA methylation profiles correlate with differential
adaptation of breast cancer cells to the antiestrogens tamoxifen and
fulvestrant. Cancer Research 2006, 66(24):11954-11966.
17. Lim YCLL, Desta Z, Zhao Q, Rae JM, Flockhart DA, Skaar TC: Endoxifen, a
secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar
changes in global gene expression patterns in MCF-7 breast cancer
cells. J Pharm Exp Ther 2006, 318:503-512.
18. Frasor J, Stossi F, Danes JM, Komm B, Lyttle CR, Katzenellenbogen BS:
Discrimination of Agonistic versus Antagonistic Activities by Gene
Expression Profiling in Breast Cancer Cells. Cancer Research 2004,
164:1522-1533.
19. Cicatiello L, Mutarelli M, Grober OM, Paris O, Ferraro L, Ravo M, Tarallo R,
Luo S, Schroth GP, Seifert M, Zinser C, Chiusano ML, Traini A, De Bortoli M,
Weisz A: Estrogen receptor alpha controls a gene network in luminal-like
breast cancer cells comprising multiple transcription factors and
microRNAs. American Journal of Pathology 2010, 176(5):2113-2130.
20. Lee TI, Rinaldi NJ, Robert F, Odom DT, Bar-Joseph Z, Gerber GK,
Hannett NM, Harbison CT, Thompson CM, Simon I, Zeitlinger J,
Jennings EG, Murray HL, Gordon DB, Ren B, Wyrick JJ, Tagne JB, Volkert TL,
Fraenkel E, Gifford DK, Young RA: Transcriptional regulatory networks in
Saccharomyces cerevisiae. Science 2002, 298:799-804.
21. Neve RMCK, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N,
Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ,
Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F,
Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW: A
collection of breast cancer cell lines for the study of functionally distinct
cancer subtypes. Cancer Cell 2006, 10:515-527.
22. Li LCA, Jin VX, Paik HH, Fan M, Li X, Zhang W, Robarge J, Balch C,
Davuluri RV, Kim S, Huang TH, Nephew KP: A mixture model-based
discriminate analysis for identifying ordered transcription factor binding
site pairs in gene promoters directly regulated by estrogen receptor-
alpha. Bioinformatics 2006, 22:2210-2216.
23. Lin ZRS, Huang CC, Bulun SE: Novel estrogen receptor-alpha binding sites and
estradiol target genes identified by chromatin immunoprecipitation cloning in
breast cancer 2007, 67:5017-5024.
24. Lin CY, Ström A, Vega VB, Li KS, Li YA, Thomsen JS, Chan WC, Doray B,
Bangarusamy DK, Ramasamy A, Vergara LA, Tang S, Chong A, Bajic VB,
Miller LD, Gustafsson J, Liu ET: Discovery of estrogen receptor α target
genes and response elements in breast tumor cells. Genome Biology
2004, 5:R66.
25. Cicatiello LMM, Grober OM, Paris O, Ferraro L, Ravo M, Tarallo R, Luo S,
Schroth GP, Seifert M, Zinser C, Chiusano ML, Traini A, De Bortoli M,
Weisz A: Estrogen receptor alpha controls a gene network in luminal-like
breast cancer cells comprising multiple transcription factors and
microRNAs. Am J Pathol 2010, 176:2113-2130.
26. Welboren W, van Driel MA, Janssen-Megens EM, Sweep FC, Span PN,
Stunnenberg HG: ChIP-Seq of ERa and RNA polymerase II defines genes
differentially responding to ligands. The EMBO Journal 2009, 28:1418-1428.
27. Kwon YS G-BI, Hutt KR, Cheng CS, Jin M, Liu D, Benner C, Wang D, Ye Z,
Bibikova M, Fan JB, Duan L, Glass CK, Rosenfeld MG, Fu XD: Sensitive ChIP-
DSL technology reveals an extensive estrogen receptor alpha-binding
program on human gene promoters. Proc Natl Acad Sci 2007,
104:4852-4857.
28. Hua S, Kittler R, White KP: Genomic Antagonism between Retinoic Acid
and Estrogen Signaling in Breast Cancer. Cell 2009, 137:1259-1271.
29. De Luca A, Sacchetta P, Nieddu M, Di Ilio C, Favaloro B: Important roles of
multiple Sp1 binding sites and epigenetic modifications in the
regulation of the methionine sulfoxide reductase B1 (MsrB1) promoter.
BMC Molecular Biology 2007, 8:39.
30. Asangani IARS, Leupold JH, Post S, Allgayer H: NRF-1, and AP-1 regulate
the promoter of the human calpain small subunit 1 (CAPNS1) gene.
Gene 2008, 410(1):197-206.
31. Jin VX, Rabinovich A, Squazzo SL, Green R, Farnham PJ: A computational
genomics approach to identify cis-regulatory modules from chromatin
immunoprecipitation microarray data–a case study using E2F1. Genome
Research 2006, 16(12):1585-1596.
32. Wenzel K, Daskalow K, Herse F, Seitz S, Zacharias U, Schenk JA, Schulz H,
Hubner N, Micheel B, Schlag PM, Osterziel KJ, Ozcelik C, Scherneck S,
Jandrig B: Expression of the protein phosphatase 1 inhibitor KEPI is
downregulated in breast cancer cell lines and tissues and involved in
the regulation of the tumor suppressor EGR1 via the MEK-ERK pathway.
Biological Chemistry 2007, 388(5):489-495.
33. Deblois G, Giguere V: Nuclear Receptor Location Analyses in Mammalian
Genomes: From Gene Regulation to Regulatory Networks. Molecular
Endocrinology 2008, 22(9):1999-2011.
34. Kininis M, Kraus WL: A global view of transcriptional regulation by
nuclear receptors: gene expression, factor localization, and DNA
sequence analysis. Nuclear Receptor Signaling 2008, 6:e005.
35. McGarvey KM, Van Neste L, Cope L, Ohm JE, Herman JG, Van Criekinge W,
Schuebel KE, Baylin SB: Defining a chromatin pattern that characterizes
DNA-hypermethylated genes in colon cancer cells. Cancer Research 2008,
68(14):5753-5759.
36. Lupien MEJ, Meyer CA, Wang Q, Zhang Y, Li W, Carroll JS, Liu XS, Brown M:
FoxA1 translates epigenetic signatures into enhancer-driven lineage-
specific transcription. Cell 2008, 132(6):958-970.
37. Bracken APDN, Pasini D, Hansen KH, Helin K: Genome-wide mapping of
Polycomb target genes unravels their roles in cell fate transitions. Genes
Dev 2006, 20:1123-1136.
38. Kondo YSL, Cheng AS, Ahmed S, Boumber Y, Charo C, et al: Gene silencing
in cancer by histone H3lysine 27 trimethylation independent of
promoter DNA methylation. Nat Genet 2008, 2008:741-750.
39. McGarvey KMVNL, Cope L, Ohm JE, Herman JG, Van Criekinge W, et al:
Defining a chromatin pattern that characterizes DNA-hypermethylated
genes in colon cancer cells. Cancer Res 2008, 68:5753-5759.
Shen et al. BMC Systems Biology 2011, 5:67
http://www.biomedcentral.com/1752-0509/5/67
Page 15 of 1640. Schlesinger YSR, Keshet I, Farkash S, Hecht M, Zimmerman J, et al:
Polycomb-mediated methylation on Lys27 of histone H3 pre-marks
genes for de novo methylation in cancer. Nature Genetics 2007,
39:232-236.
41. Balch CNK, Huang TH, Bapat SA: Epigenetic “bivalently marked” process
of cancer stem cell driven tumorigenesis. Bioessays 2007, 29:842-845.
42. Li MPH, Balch C, Kim Y, Li L, Huang TH, Nephew KP, Kim S: Enriched
transcription factor binding sites in hypermethylated gene promoters in
drug resistant cancer cells. Bioinformatics 2008, 24(16):1745-1748.
43. Lee TI, Johnstone SE, Young RA: Chromatin immunoprecipitation and
microarray-based analysis of protein location. Nature Protocol 2006,
1(2):729-748.
44. Feng W, Liu Y, Wu J, Nephew KP, Huang TH, Li L: A Poisson mixture
model to identify changes in RNA polymerase II binding quantity using
high-throughput sequencing technology. BMC Genomics 2008, 9(suppl 2):
S23.
45. Huang YW, Liu JC, Deatherage DE, Luo J, Mutch DG, Goodfellow PJ,
Miller DS, Huang TH: Epigenetic repression of microRNA-129-2 leads to
overexpression of SOX4 oncogene in endometrial cancer. Cancer
Research 2009, 69(23):9038-9046.
46. Newton MA KCM, Richmond CS, Blattner FR, Tsui KW: On differential
variability of expression ratio: improving statistical inference about gene
expression changes from microarray data. Journal of Computational
Biology 2001, 8:37-52.
47. Kendziorski CM, Newton MA, Lan H, Gould MN: On parametric empirical
Bayes methods for comparing multiple groups using replicated gene
expression profiles. Statistic in Medicine 2003, 22:3899-3914.
48. Newton MA, Noueiry A, Sarkar D, Ahlquist P: Detecting differential gene
expression with a semiparametric hierarchical mixture method.
Biostatistics 2004, 5(2):155-176.
49. Johnson WE, Li W, Meyer CA, Gottardo R, Brown M, Liu XS: Model-based
analysis of tiling-arrays for ChIP-chip. PNAS 2006, 103(33):12457-12462.
50. Ohler U, Niemann H: Identification and analysis of eukaryotic promoters:
recent computational approaches. Trends in Genetics 2001, 17:56-60.
51. Efron B, Tibshirani R, Storey JD, Tusher VG: Empirical Bayes Analysis of a
Microarray Experiment. Journal of the American Statistical Association 2001,
96:1151-1160.
doi:10.1186/1752-0509-5-67
Cite this article as: Shen et al.: A modulated empirical Bayes model for
identifying topological and temporal estrogen receptor a regulatory
networks in breast cancer. BMC Systems Biology 2011 5:67.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Shen et al. BMC Systems Biology 2011, 5:67
http://www.biomedcentral.com/1752-0509/5/67
Page 16 of 16